Search - tctmd.com

Displaying 1 - 20 of 54

Sort: Relevancy | Date

Presentation Fellows 2021

Stent Design: Past, Present and Future

Presenter: Gregg W. Stone

May 08, 2021

Presentation

Response by David Taggart, MD, PhD to the EXCEL Statement

Presenter: David Taggart

December 19, 2019

Presentation Fellows 2019

Stent Technology:Past, Present and Future

Presenter: Gregg W. Stone

April 12, 2019

Presentation CHIP at ACC 2018

Update on PCI for LMCA and Multivessel Disease

Presenter: Gregg W. Stone

March 09, 2018

Presentation JIM 2018

Overview of New Generation Drug-Eluting Stents

Presenter: Gregg W. Stone

February 22, 2018

Presentation CHIP Washington DC 2017

A Brief Update of PCI for Left Main Disease: Perspectives After the EXCEL and NOBLE Trials

Presenter: Gregg W. Stone

March 21, 2017

Presentation JIM 2017

Bioresorbable Scaffolds: A Real Clinical Need? Yes!

Presenter: Gregg W. Stone

February 10, 2017

Presentation JIM 2017

Bioresorbable Scaffolds: An Important Clinical Need

Presenter: Gregg W. Stone

February 08, 2017

Presentation JIM 2017

FANTOM: A Radio-opaque Desaminotyrosine Polycarbonate-based Scaffold

Presenter: Gregg W. Stone

February 08, 2017

Presentation JIM 2017

Perspectives on the ABSORB Randomized Trials: Take-home Messages for the Clinical Practitioner

Presenter: Gregg W. Stone

February 08, 2017

Presentation TCT 2016

EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

Presenter: Martin B. Leon, Keith G. Oldroyd, Gregg W. Stone

October 31, 2016

Presentation TCT 2016

BIONICS: A Prospective, Randomized Trial of a Ridaforolimus-Eluting Coronary Stent vs a Zotarolimus-Eluting Stent in a More-Comers Population of Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Wayne B. Batchelor, David E. Kandzari

October 30, 2016

Presentation TCT 2016

BIO-RESORT (TWENTE III): A Prospective, Randomized Three-Arm Trial Comparing Two Different Biodegradable Polymer-Based Drug-Eluting Stents and a Durable Polymer-Based Drug-Eluting Stent in an All-Comers Population of Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Wayne B. Batchelor, Clemens von Birgelen

October 30, 2016

Presentation Fellows 2016

Drug-Eluting Stents: Past, Present, and Future

Presenter: Gregg Stone

April 15, 2016

Presentation ACC 2016

Outcomes of the ABSORB Bioresorbable Vascular Scaffold in Very Small and Not Very Small Coronary Arteries: The ABSORB III randomized trial

Presenter: Gregg W. Stone

April 03, 2016

Presentation

1-Year Outcomes With Absorb BVS: Patient-Level, Pooled Meta-Analysis

Presenter: Gregg Stone

March 29, 2016

Presentation JIM 2016

The Drug-Filled Stent and the Start of RevElution

Presenter: Gregg W. Stone

February 10, 2016

Presentation JIM 2016

ABSORB BVS:What Have we Learned?

Presenter: Gregg W. Stone

February 09, 2016

Presentation

AHA Late Breaking Trials: What's more appropriate? IVUS or appropriate use criteria?

Presenter: Gregg W. Stone

January 19, 2016

Presentation

TCT 2015 Late Breaking Trials: LEADERS FREE and RESPECT LATE

Presenter: Gregg W. Stone

November 23, 2015

Advertisement

Stent Design: Past, Present and Future

Response by David Taggart, MD, PhD to the EXCEL Statement

Stent Technology:Past, Present and Future

Update on PCI for LMCA and Multivessel Disease

Overview of New Generation Drug-Eluting Stents

A Brief Update of PCI for Left Main Disease: Perspectives After the EXCEL and NOBLE Trials

Bioresorbable Scaffolds: A Real Clinical Need? Yes!

Bioresorbable Scaffolds: An Important Clinical Need

FANTOM: A Radio-opaque Desaminotyrosine Polycarbonate-based Scaffold

Perspectives on the ABSORB Randomized Trials: Take-home Messages for the Clinical Practitioner

EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

BIONICS: A Prospective, Randomized Trial of a Ridaforolimus-Eluting Coronary Stent vs a Zotarolimus-Eluting Stent in a More-Comers Population of Patients With Coronary Artery Disease

BIO-RESORT (TWENTE III): A Prospective, Randomized Three-Arm Trial Comparing Two Different Biodegradable Polymer-Based Drug-Eluting Stents and a Durable Polymer-Based Drug-Eluting Stent in an All-Comers Population of Patients With Coronary Artery Disease

Drug-Eluting Stents: Past, Present, and Future

Outcomes of the ABSORB Bioresorbable Vascular Scaffold in Very Small and Not Very Small Coronary Arteries: The ABSORB III randomized trial

1-Year Outcomes With Absorb BVS: Patient-Level, Pooled Meta-Analysis

The Drug-Filled Stent and the Start of RevElution

ABSORB BVS:What Have we Learned?

AHA Late Breaking Trials: What's more appropriate? IVUS or appropriate use criteria?

TCT 2015 Late Breaking Trials: LEADERS FREE and RESPECT LATE

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content